- Types of Eczema
- Eczema in Children
- Living Well
- Eczema Products
- Get Involved
- For Medical Professionals
Phase IIa, Multicentre, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Safety, Tolerability and Efficacy of Treatment With BI 655130 in Adult Patients With Moderate to Severe Atopic Dermatitis
The primary objective of this trial is to investigate the safety, tolerability and efficacy of BI 655130 in patients with Atopic Dermatitis (AD) following repeated intravenous administrations compared to placebo.
18 Years to 75 Years
– Signed and dated written informed consent in accordance with Good Clinical Practice
(GCP) and local legislation prior to the start of any screening procedures
– Male or female patients, 18 to 75 years of age at screening
– Diagnosis of atopic dermatitis for at least 1 year
– Moderate to severe atopic dermatitis defined as:
– At least 10% Body Surface Area (BSA) of atopic dermatitis involvement at
screening and baseline
– Eczema Area and Severity Index (EASI) of at least 12 at screening and at least 16
– Investigator Global Assessment (IGA) of at least 3 at screening and baseline
– Documented history of inadequate response to topical corticosteroid as judged by the
– Willing to use a standard emollient for the duration of the study
– Women of childbearing potential (WOCBP) must be ready and able to use highly effective
methods of birth control per ICH M3 (R2) that result in a low failure rate of less
than 1% per year when used consistently and correctly. A list of contraception methods
meeting these criteria is provided in the patient information.
– Use of topical corticosteroids or other agents for atopic dermatitis within 7 days
prior to first dose of trial treatment.
– Use of systemic corticosteroids or other agents for atopic dermatitis within 4 weeks
prior to first dose of trial treatment.
– Women who are pregnant, nursing, or who plan to become pregnant while in the trial.
Women who stop nursing before the study drug administration do not need to be excluded
from participating; they should refrain from breastfeeding up to 16 weeks after the
last study drug administration
– Patient with a transplanted organ (with exception of a corneal transplant > 12 weeks
prior to screening) or who have ever received stem cell therapy (e.g., Prochymal).
– Any documented active or suspected malignancy or history of malignancy within 5 years
prior to the screening visit, except appropriately treated basal cell carcinoma of the
skin, squamous cell carcinoma of the skin or in situ carcinoma of uterine cervix.
– Use of any restricted medication or any drug considered likely to interfere with the
safe conduct of the study, as assessed by the investigator.
– History of allergy/hypersensitivity to the systemically administered trial medication
agent or its excipients.
– Active systemic infections (Fungal and bacterial disease) during the last 2 weeks
prior to first drug administration, per investigator assessment.
– Relevant chronic or acute infections (exception: common cold) including human
immunodeficiency virus (HIV) or viral hepatitis. A patient can be re-screened if the
patient was treated and is cured from the acute infection.
– Active or Latent Tuberculosis (TB):
– Patients with active tuberculosis are excluded.
– Patients with a positive QuantiFERON TB test during screening are excluded,
– Patient had previous diagnosis of active or latent TB and has completed
appropriate treatment per local practice/guidelines within the last 3 years
and at least 6 months before first administration of trial medication under
this protocol (patients may be re-screened once to meet this criterion)
– Patients with suspected false positive or indeterminate QuantiFERON TB
result may be re-tested once
– If the QuantiFERON TB test result is not available or provides indeterminate
results after repeat testing: A tuberculin skin test reaction ≥10mm (≥5mm if
receiving ≥15mg/d prednisone or its equivalent) is considered positive.
– Currently enrolled in another investigational device or drug trial, or less than 30
days or 5 half lives, whichever is longer since ending another investigational device
or drug trial(s), or receiving other investigational treatment(s).
– Evidence of a current or previous disease, medical condition (including chronic
alcohol or drug abuse or any condition) other than AD, surgical procedure, psychiatric
or social problems, medical examination finding (including vital signs and ECG), or
laboratory value at the screening outside the reference range that in the opinion of
the investigator is clinically significant and would make the study participant
unreliable to adhere to the protocol, comply with all study visits/procedures or to
complete the trial, compromise the safety of the patient or compromise the quality of
– Major surgery (major according to the investigator) performed within 12 weeks prior to
first study drug adminstration or planned during the study (e.g. hip replacement,
aneurysm removal, stomach ligation).
– Severe, progressive, or uncontrolled hepatic disease, defined as >3-fold Upper Limit
of Normal (ULN) elevation in AST or ALT or alkaline phosphatase, or >2-fold ULN
elevation in total bilirubin.
Please refer to this study by its ClinicalTrials.gov identifier: NCT03822832
Center for Dermatology and Plastic Surgery
Scottsdale, Arizona 85260
Northwest Arkansas Clinical Trials Center, PLLC
Rogers, Arkansas 72758
Clinical Physiology Associates
Fort Myers, Florida 33912
Finlay Medical Research Corp
Miami, Florida 33126
University of South Florida
Tampa, Florida 33612
ForCare Clinical Research, Inc.
Tampa, Florida 33613
The Indiana Clinical Trials Center, PC
Plainfield, Indiana 46168
Greenwich Village Dermatology
New York, New York 10012
Unity Clinical Research
Oklahoma City, Oklahoma 73118
Dermatology Treatment and Research Center, PA
Dallas, Texas 75230
Progressive Clinical Research
San Antonio, Texas 78213
Center for Clinical Studies
Webster, Texas 77598
University of Alberta Hospital (University of Alberta)
Edmonton, Alberta T6G 2B7
NewLab Clinical Research Inc.
St. John's, Newfoundland and Labrador A1C 2H5
Innovaderm Research Inc.
Montreal, Quebec H2K 4L5
Etienne Saint-Cyr Proulxesaint-Cyr@innovaderm.ca
Aichi Medical University Hospital
Aichi, Nagakute, 480-1195
National Hospital Organization Kyushu Medical Center
Fukuoka, Fukuoka, 810-8563
Fukuoka University Hospital
Fukuoka, Fukuoka, 814-0180
Kurume University Hospital
Fukuoka, Kurume, 830-0011
Gifu University Hospital
Gifu, Gigu, 501-1194
Tennocho Ekimae Dermatology and Allergology
Kanagawa, Yokohama, 240-0004
University Hospital Kyoto Prefectural University of Medicine
Kyoto, Kyoto, 602-8566
Nagasaki University Hospital
Nagasaki, Nagasaki, 852-8501
Osaka City University Hospital
Osaka, Osaka, 545- 8586
Tokyo Medical University Hachioji Medical Center
Tokyo, Hachioji, 193-0998
Showa University Hospital
Tokyo, Shinagawa-ku, 142-8666